METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs).

Founded in 1978, the Controlled Release Society is the world's foremost nonprofit scientific organization dedicated to advanced drug delivery. At this year's meeting, METiS Technologies stood out as the only Chinese biotechnology company participating with a featured poster presentation. Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS and a Member of the U.S. National Academy of Engineering, together with Dr. Andong Liu, Vice President of METiS, presented the poster titled: "AI-Empowered LNP Discovery for Organ-Targeted RNA Delivery."

The AiLNP platform is METiS' proprietary AI-driven system for nucleic acid delivery design. It integrates a de novo lipid generation foundation model, a high-throughput microfluidics-based LNP assembly and screening system, and a large-scale, proprietary lipid library. Collectively, these innovations expand the design space of nanomaterials by over 1,000-fold compared to conventional approaches—effectively overcoming long-standing discovery bottlenecks in the field.

By combining predictive AI models with molecular dynamics simulations, the AiLNP platform provides mechanistic insights into lipid behavior and enables prediction of more than 10 physicochemical parameters. It further allows for rational design and optimization of LNP components and ratios to construct customized, high-performance delivery systems.

Key findings from the poster highlight the platform's ability to accelerate LNP design cycles while significantly improving discovery speed and quality across multiple tissue targets:

Liver-targeted LNPs developed through AiLNP demonstrated best-in-class performance for gene editing, achieving high efficiency and safety in NHPs. Using CRISPR-Cas9-mediated TTR knockdown as a model, LNP developed by AiLNP achieved ~90% reduction in serum TTR levels with only a transient, mild elevation in liver enzymes.

Lung-targeted LNPs exhibited high delivery efficiency and specificity in rodents, with successful translation to NHPs. At the cellular level, these LNPs transfected a broad range of pulmonary cell types in NHPs—including stem-like cells, alveolar type II cells (>30%), and airway basal cells (>10%) at 1 mg/kg—supporting their potential for durable genetic correction.

METiS' Musle-targeted LNPs also enabled successful in vivo delivery and gene editing in multiple types of muscle cells in mice.

 "This year's CRS theme, 'Next-Generation Delivery Innovation', reflects the rapid evolution in drug delivery technologies. Among the 410 accepted posters across 12 research tracks, more than 200 focused on nanomedicine, nanodelivery, and gene editing—demonstrating these as the most active areas of exploration," said Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS Technologies. "We're pleased to present our findings at the world's premier scientific forum for drug delivery and remain committed to pushing the boundaries of LNP discovery."

Dr. Chris Lai, Co-founder and CEO of METiS, added: "Since day one, METiS has been positioning at the global forefront of AI-powered nanomaterial innovation. We believe nanodelivery is the critical enabler of the next generation of programmable medicines—and that AI will be the key catalyst driving this transformation."

AI Nanodelivery for a Healthier Future. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design.

METiS' platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives. 

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs).

Founded in 1978, the Controlled Release Society is the world's foremost nonprofit scientific organization dedicated to advanced drug delivery. At this year's meeting, METiS Technologies stood out as the only Chinese biotechnology company participating with a featured poster presentation. Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS and a Member of the U.S. National Academy of Engineering, together with Dr. Andong Liu, Vice President of METiS, presented the poster titled: "AI-Empowered LNP Discovery for Organ-Targeted RNA Delivery."

The AiLNP platform is METiS' proprietary AI-driven system for nucleic acid delivery design. It integrates a de novo lipid generation foundation model, a high-throughput microfluidics-based LNP assembly and screening system, and a large-scale, proprietary lipid library. Collectively, these innovations expand the design space of nanomaterials by over 1,000-fold compared to conventional approaches—effectively overcoming long-standing discovery bottlenecks in the field.

By combining predictive AI models with molecular dynamics simulations, the AiLNP platform provides mechanistic insights into lipid behavior and enables prediction of more than 10 physicochemical parameters. It further allows for rational design and optimization of LNP components and ratios to construct customized, high-performance delivery systems.

Key findings from the poster highlight the platform's ability to accelerate LNP design cycles while significantly improving discovery speed and quality across multiple tissue targets:

Liver-targeted LNPs developed through AiLNP demonstrated best-in-class performance for gene editing, achieving high efficiency and safety in NHPs. Using CRISPR-Cas9-mediated TTR knockdown as a model, LNP developed by AiLNP achieved ~90% reduction in serum TTR levels with only a transient, mild elevation in liver enzymes.

Lung-targeted LNPs exhibited high delivery efficiency and specificity in rodents, with successful translation to NHPs. At the cellular level, these LNPs transfected a broad range of pulmonary cell types in NHPs—including stem-like cells, alveolar type II cells (>30%), and airway basal cells (>10%) at 1 mg/kg—supporting their potential for durable genetic correction.

METiS' Musle-targeted LNPs also enabled successful in vivo delivery and gene editing in multiple types of muscle cells in mice.

 "This year's CRS theme, 'Next-Generation Delivery Innovation', reflects the rapid evolution in drug delivery technologies. Among the 410 accepted posters across 12 research tracks, more than 200 focused on nanomedicine, nanodelivery, and gene editing—demonstrating these as the most active areas of exploration," said Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS Technologies. "We're pleased to present our findings at the world's premier scientific forum for drug delivery and remain committed to pushing the boundaries of LNP discovery."

Dr. Chris Lai, Co-founder and CEO of METiS, added: "Since day one, METiS has been positioning at the global forefront of AI-powered nanomaterial innovation. We believe nanodelivery is the critical enabler of the next generation of programmable medicines—and that AI will be the key catalyst driving this transformation."

AI Nanodelivery for a Healthier Future. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design.

METiS' platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives. 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

Dubai: Global platform for digital commerce and new economy

DUBAI, UAE, Dec. 30, 2025 /PRNewswire/ -- A new milestone reflecting Dubai's global leadership in customs innovation, Dubai Customs' innovative cross-border e-commerce platform has received widespread praise from the World Customs Organization (WCO), in a special trilingual report on it (French, English, and Spanish). The report confirms that Dubai Customs serves as a global model for digital transformation. This success story proves that customs services innovation and border control are attainable through effective policies, strong partnerships, and advanced technology.

 

 

This interest highlights the UAE's thriving e-commerce sector, creating thousands of jobs and advancing our leadership's vision for growth. The volume of goods transported by sea and air in the Emirate of Dubai has also recorded remarkable growth, achieving Dubai's D33 vision of becoming a global hub for economic expansion driven by logistics and digital commerce.

Reflecting strong market growth, UAE e-commerce reached AED 32.3 billion ($8.8 billion) in 2024 and is forecast at AED 50.6 billion ($13.8 billion) by 2029. Supporting this, Dubai Customs targets converting 20–30% of low-value e-commerce shipments to its platform. Through cooperation with multinational express couriers and SMEs, Dubai Customs ensures that all parties benefit from advanced trade facilitation. The platform's scope extends regionally, supporting e-commerce routes across the GCC. These goals support the Dubai Economic Agenda (D33) , which aims to double the economy within a decade , rank Dubai among the top three economic cities , and position it as a top five global logistics hub.

Commenting on this global achievement, Juma Al Ghaith, Advisor to the Director General and Chief Executive Officer of Artificial Intelligence at Dubai Customs, emphasized that the World Customs Organization's praise reflects the depth of the transformation led by Dubai Customs in the world of trade and e-commerce, and embodies the vision of the wise leadership in making Dubai the city of the future and a global hub for the new economy.

Atiq Al Muhairi, Executive Director of Customs Development at Dubai Customs, said: "Dubai Customs' e-commerce platform is a qualitative leap and a new benchmark in facilitating cross-border trade by strengthening the link between government entities and shipping companies, enabling companies to comply with customs requirements quickly and easily, and aligning the logistics system with e-commerce traffic."

He added: "According to a report by the WCO, the platform globally demonstrates how technology effectively facilitates trade."

 

 

 

Dubai: Global platform for digital commerce and new economy

DUBAI, UAE, Dec. 30, 2025 /PRNewswire/ -- A new milestone reflecting Dubai's global leadership in customs innovation, Dubai Customs' innovative cross-border e-commerce platform has received widespread praise from the World Customs Organization (WCO), in a special trilingual report on it (French, English, and Spanish). The report confirms that Dubai Customs serves as a global model for digital transformation. This success story proves that customs services innovation and border control are attainable through effective policies, strong partnerships, and advanced technology.

 

 

This interest highlights the UAE's thriving e-commerce sector, creating thousands of jobs and advancing our leadership's vision for growth. The volume of goods transported by sea and air in the Emirate of Dubai has also recorded remarkable growth, achieving Dubai's D33 vision of becoming a global hub for economic expansion driven by logistics and digital commerce.

Reflecting strong market growth, UAE e-commerce reached AED 32.3 billion ($8.8 billion) in 2024 and is forecast at AED 50.6 billion ($13.8 billion) by 2029. Supporting this, Dubai Customs targets converting 20–30% of low-value e-commerce shipments to its platform. Through cooperation with multinational express couriers and SMEs, Dubai Customs ensures that all parties benefit from advanced trade facilitation. The platform's scope extends regionally, supporting e-commerce routes across the GCC. These goals support the Dubai Economic Agenda (D33) , which aims to double the economy within a decade , rank Dubai among the top three economic cities , and position it as a top five global logistics hub.

Commenting on this global achievement, Juma Al Ghaith, Advisor to the Director General and Chief Executive Officer of Artificial Intelligence at Dubai Customs, emphasized that the World Customs Organization's praise reflects the depth of the transformation led by Dubai Customs in the world of trade and e-commerce, and embodies the vision of the wise leadership in making Dubai the city of the future and a global hub for the new economy.

Atiq Al Muhairi, Executive Director of Customs Development at Dubai Customs, said: "Dubai Customs' e-commerce platform is a qualitative leap and a new benchmark in facilitating cross-border trade by strengthening the link between government entities and shipping companies, enabling companies to comply with customs requirements quickly and easily, and aligning the logistics system with e-commerce traffic."

He added: "According to a report by the WCO, the platform globally demonstrates how technology effectively facilitates trade."

 

 

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

World Customs Organization praises 'e-commerce platform' in trilingual report